Rationale: Gitelman syndrome (GS) is a rare autosomal recessive hereditary salt-losing tubulopathy caused by loss-of-function mutations in the SLC12A3 gene. It is usually characterized by hypokalemia, metabolic alkalosis, hypomagnesemia, and hypocalciuria. There are only a few reports on GS combined with growth hormone deficiency (GHD).
Introduction
Gitelman syndrome (GS) is a rare autosomal recessive hereditary salt-losing tubulopathy with a characteristic set of metabolic abnormalities, including hypokalemia, hypomagnesemia, metabolic alkalosis, and hypocalciuria. [1] The GS phenotype is usually caused by loss-of-function mutations in the SLC12A3 gene which encodes the thiazide-sensitive sodium chloride cotransporter channel in the distal convoluted tubule of the kidney. Clinically, these patients may present with fatigue, tetany, cramps, muscle weakness, vomiting, diarrhea, and abdominal pain. [2] In addition, growth retardation was noted in some patients with GS. [3] Although potassium depletion may have some negative effects on growth, the pathogenesis of growth retardation in GS is still unclear. There are few reports on GS combined with growth hormone deficiency (GHD). [4] [5] [6] [7] Herein, we describe 3 cases of patients with GS combined with GHD.
Clinical case

Case 1
A 6-year, 2-month-old boy was admitted to our hospital complaining of a 4-day history of weakness. His birth weight was 3.00 kg. No family history of endocrine, renal, celiac, and cardiovascular diseases or history of diuretic use was noted. Blood pressure was normal (91/63 mmHg). Initial biochemical analysis revealed metabolic alkalosis with hypokalemia (Table 1) based on the following values: serum total calcium level was 2.40 mmol/L (normal range: 2.20-2.65 mmol/L), phosphorus was 1.25 mmol/L (normal range: 1.29-2.26 mmol/L), and serum magnesium level was very low compared to the normal range. Further investigations revealed high serum renin and aldosterone levels. The 24-hour urinalysis showed that calcium was 2.5 mg/ 24 hour, significantly lower than the normal range of 100-300 mg/24 hour. The patient had normal adrenal, hepatic, renal, parathyroid, and thyroid function. Abdominal ultrasound showed that the kidneys and liver were normal. Whole blood DNA sequencing revealed 2 heterozygous mutations in the SLC12A3 gene (c.473G>A p.R158Q and c.602-16G>A p. splicing) ( Table 2) . Administration of oral replacement of magnesium oxide (MgO, 1 g/day), potassium chloride (KCl, 2.0 g/day), and spironolactone (2 mg/kg·day À1 ) was done. Serum potassium and magnesium levels increased to 3.0 mmol/L and 0.85 mmol/L, respectively. The frequency of weakness significantly decreased. However, his growth rate was just 4.2 cm/year, slightly higher than that before MgO and KCl therapy, which was only 3.2 cm/year.
His height was 108 cm (À2.78 standard deviation score [SDS]) and his weight was 18.7 kg (À1.58 SDS) at 9.50 years. The pubertal stage was genitalia stage I and pubic hair stage I, and his bone age (BA), according to the Greulich-Pyle method, was 6 years old. Growth hormone stimulation tests (GHSTs) (L-dopa and arginine) for short stature identified GHD, the peak GH level was 6.00 ng/mL (see Table 1 ). Pituitary MRI revealed no remarkable findings. The patient was treated with 0.277 mg/kg/week of recombinant human growth hormone (rhGH), and he achieved a 10.6-cm height gain over 11 months. Table 2 ). She received oral replacement of 1.5 g/day MgO, 3.0 g/day KCl, and spironolactone (2 mg/kg·day À1 ). Within 3 months of treatment, serum potassium and magnesium levels increased to 3.1 mmol/L and 0.83 mmol/L, respectively. At that time, her growth velocity was 3.6 cm/year. Then, GHST was performed and GHD was identified, the peak GH level was 6.88 ng/mL (see Table 1 ). No remarkable findings were shown based on pituitary MRI. She was treated with 0.280 mg/kg/week of rhGH and achieved a 3.2-cm height gain over the first 3 months.
Case 3
A year. Then, GHSTs were performed and GHD was identified, the peak GH level was 3.30 ng/mL (see Table 1 ). Hence, he was treated with 0.300 mg/kg/week of rhGH and achieved a 2.8-cm height gain over the first 3 months.
Discussion
GS is an autosomal recessive salt-losing renal tubulopathy with a characteristic set of hypokalemic metabolic alkalosis, hypomagnesemia, and hypocalciuria. Epidemiologic studies showed that the prevalence of GS was approximately 1 per 40,000 among Europeans. [8] Patients were diagnosed with GS based on their clinical features and biochemical parameters. Symptoms of GS include spasm, weakness, and numbness. However, these symptoms are usually nonspecific and variable. Thus, the typical laboratory findings which include hypokalemia, metabolic alkalosis, hypomagnesemia, and hypocalciuria are much more important. However, hypomagnesemia and hypocalciuria are not always present in patients with GS. Therefore, genetic testing is the optimal standard for the diagnosis of GS. It was reported that GS is usually caused by loss-of-function mutations in the SLC12A3 (solute carrier family 12 member 3) gene, encoding the thiazide-sensitive sodium chloride (NaCl) cotransporter protein.
Inactivation of SLC12A3 gene mutation reduces NaCl reabsorption in the distal convoluted tubule and causes the symptoms of GS. To date, more than 400 mutations throughout the SLC12A3 gene have been identified in different ethnic groups. Recently, 2 studies on GS gene mutations among Chinese patients were reported. These results showed that the D486N mutation of the SLC12A3 gene appeared to be more frequent than the other mutations in Chinese patients with GS. [9, 10] This study also found that 1 of the 3 patients had the same mutation. Although mutations have also been identified in the chloride voltage-gated channel Kb (CLCNKB) gene in a minority of patients with atypical GS phenotypes, we did not find any mutation of CLCNKB gene in our 3 patients. One research from China showed that nearly 30% of Chinese patients with GS carried 0 or just 1 mutant allele; they failed to have a genetic diagnosis of GS based on autosomal recessive inheritance. This might be attributed to undetected large genomic rearrangements and deep intronic mutations, which account for a considerable proportion of GS patients, by direct sequencing. [9] Although the gene analysis results are not the only criteria for GS diagnosis, genetic analysis is still recommended for all suspected patients. A majority of GS patients may present with weakness, muscle cramps, paresthesias, and episodes of tetany or paralysis. Meanwhile, other symptoms, such as nocturia, polydipsia, diarrhea, dizziness, and salt craving are included. These symptoms are all related to electrolyte and acid-base abnormalities. GS is associated with less severe growth retardation, compared with Bartter syndrome (BS). There are some factors that may contribute to growth retardation in BS or GS. Significant salt loss in the antenatal-neonatal period, hypokalemia, or metabolic alkalosis may have some effect on growth.
However, the precise causes of growth retardation remain unclear. Some cases investigating GS combined with GHD have been reported in the last 2 decades, [4] [5] [6] [7] as shown in Table 3 . Moreover, because classic BS and GS shared the laboratory finding of hypokalemic alkalosis, Adachi et al [11] conjectured that some of the older cases reported in the literature do not comply with the current definition and concept of BS and thus, should be recognized as GS.
Experimental studies suggested that potassium depletion could have a negative effect on growth by reducing the circulating levels of growth hormone and insulin-like growth factor 1 (IGF-1), which may blunt the GH response and lead to false-negative results in GHST. [12, 13] However, another study showed there was abnormal chondrocyte maturation in rats which fed a potassiumfree diet, and it was not normalized by a high dose of exogenous GH. This observation can easily explain why there is resistance to GH in hypokalemic rats. [13] The excellent response to GH therapy made us believe that GHD should be regarded as a complication in classic BS or GS, which is similar with the other study. [5, 11, 14] It has also been reported that higher urine magnesium excretion alters the GH/IGF-1 axis in a type 1 diabetes mellitus cohort. [15] Matsuzaki et al [16] reported that magnesium deficiency increases serum fibroblast growth factor 23 (FGF-23) levels in rats. Another research showed that FGF-23 altered the GH/IGF-1 axis, delayed puberty, malnutrition, and metabolic acidosis. [17] Additionally, these researches demonstrated that hypomagnesemia may play an important role in the GH/IGF-1 axis. However, our patients underwent GHST when the serum magnesium concentration return to normal range after therapy. Our result showed that there might be no direct relationship between hypomagnesemia and GHD. In summary, GHD should be regarded as a complication of GS in these three patients, although the exact cause of GS combined with GHD remains unclear.
In our study, all three patients received rhGh therapy and exhibited a growth velocity of 10.3-12.8 cm/year, significantly higher than before. No impaired glucose metabolism or other side effects were found in our three patients during the treatment. Our result was similar with some other researches which also reported that rhGH therapy markedly improved GS patients' growth rate. Interestingly, rhGH treatment also seemed to be helpful for the correction of hypomagnesemia, [5] we suggest that rhGH therapy might be considered in short children with GS, even though they do not suffer from GHD.
In summary, we reported three cases of GS combined with GHD. GS should be diagnosed based on the clinical manifestations and laboratory results. We propose that all patients with GS should undergo genetic test. When these patients suffer from growth retardation, GHD should be considered and GHST should be performed. rhGH therapy is helpful for stimulating the patients' growth and increasing the serum magnesium level.
